In addition, the CHEK2 gene showed significantly higher mutation rates in patients with no triple-negative BC versus patients with a triple-negative BC tumor phenotype (3.3% vs. 0.8%, p-value = 0.002). This evidence concerns the gene CHEK2 and breast cancer.